Drugmaker Eli Lilly investing US$450mil to expand output

Eli Lilly has been struggling to meet strong demand for its incretin products, which include its blockbuster diabetes drug Trulicity and the recently launched Mounjaro. — Reuters

NEW YORK: Eli Lilly and Co plans to invest an additional US$450mil (RM1.92bil) to expand capacity of a plant in North Carolina, the US drugmaker says, as it races to boost production ahead of a decision on its promising obesity treatment.

The company has been struggling to meet strong demand for its incretin products, which include its blockbuster diabetes drug Trulicity and the recently launched Mounjaro.